Experiments were not done that would confirm that the replacement or enhancement of TG2 would be protective; however, because TG2 expression is one of a limited number of enzymes implicated in tissue repair (and its expression can be induced pharmacologically10), further studies are merited to determine whether TG2 may prove a future viable target for the management of human AAA. This evidence concerns the gene TGM2 and triple-A syndrome.